3′-Methoxypuerarin

天然产物 糖类和糖苷 Saccharides and Glycosides

3′-Methoxypuerarin; 纯度: 99.90%

3′-Methoxypuerarin (3′-MOP)是从葛根中提取的异黄酮,具有神经元保护活性。

3

3′-Methoxypuerarin Chemical Structure

CAS No. : 117047-07-1

规格 价格 是否有货 数量
5 mg ¥1280 In-stock
10 mg ; 询价 ;
50 mg ; 询价 ;

* Please select Quantity before adding items.

3′-Methoxypuerarin 相关产品

bull;相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Natural Product Library
  • Medicine Food Homology Compound Library
  • Phenols Library
  • Traditional Chinese Medicine Monomer Library
  • Flavonoids Library

生物活性

3′-Methoxypuerarin (3′-MOP) is an isoflavone extracted from radix puerariae that shows neuron protection activity.

体内研究
(In Vivo)

3′-Methoxypuerarin increases the number of surviving neurons in the hippocampal CA1 region and markedly reduces the number of apoptotic pyramidal neurons after ischemia/reperfusion injury. 3′-Methoxypuerarin can protect hippocampal neurons against I/R injury by inhibiting apoptosis[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

446.40

Formula

C22H22O10

CAS 号

117047-07-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4deg;C, sealed storage, away from moisture and light

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture and light)

溶解性数据
In Vitro:;

DMSO : 250 mg/mL (560.04 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.2401 mL 11.2007 mL 22.4014 mL
5 mM 0.4480 mL 2.2401 mL 4.4803 mL
10 mM 0.2240 mL 1.1201 mL 2.2401 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.08 mg/mL (4.66 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.66 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (4.66 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.66 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.66 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.66 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Liu Y, et al. Protection by 3′-methoxypuerarin of rat hippocampal neurons against ischemia/reperfusion injury. Chin J Physiol. 2010 Apr 30;53(2):136-40.

Animal Administration
[1]

Rats[1]

Male Wistar rats, weighing 260-320 g are randomly divided into three groups (n = 8 per group). [1] I/R+3′-MOP group: the rats undergo 8 minutes of ischemia and then 3 days of reperfusion. The 3′-Methoxypuerarin (60 mg/kg i.p.) is administrated at the moment of clamping of the carotid arteries. The rats receive daily i.p. injection of 3′-Methoxypuerarin for 3 days. [2] I/R group: the rats undergo 8 minutes of ischemia and 72 h of reperfusion. The same volume of solvent (35% polyethylene glycol solution) is administrated in the same way as 3′-Methoxypuerarin. [3] Control group: the rats undergo a sham operation. Vertebral and carotid arteries are exposed but not occluded. The rats receive a daily i.p. injection of 35% polyethylene glycol solution for 3 days[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Liu Y, et al. Protection by 3′-methoxypuerarin of rat hippocampal neurons against ischemia/reperfusion injury. Chin J Physiol. 2010 Apr 30;53(2):136-40.